Guidelines for hepatobiliary cancers: treatment strategies in the East and West.
作者信息
Midorikawa Yutaka
机构信息
Department of Surgery, National Center of Neurology and Psychiatry, Tokyo, Japan.
出版信息
Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):580-584. doi: 10.21037/hbsn-23-225. Epub 2023 Jul 17.
Abstract
摘要
相似文献
1
Guidelines for hepatobiliary cancers: treatment strategies in the East and West.肝胆癌诊疗指南：东西方的治疗策略
Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):580-584. doi: 10.21037/hbsn-23-225. Epub 2023 Jul 17.
2
Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region.中东和北非地区 NCCN 肝胆肿瘤指南的修改和实施。
J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S36-40. doi: 10.6004/jnccn.2010.0123.
3
Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies.医疗机构肝胰胆恶性肿瘤病例数量对非手术治疗的肝胆恶性肿瘤患者生存率的平均治疗效果。
Surgery. 2023 Feb;173(2):289-298. doi: 10.1016/j.surg.2022.10.011. Epub 2022 Nov 17.
4
Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.增加多模态治疗选择提高了肝细胞癌的生存率，但胆道癌的生存率仍未改变。
Eur J Surg Oncol. 2019 Sep;45(9):1660-1667. doi: 10.1016/j.ejso.2019.04.002. Epub 2019 Apr 9.
5
Emerging treatment strategies in hepatobiliary cancer.肝胆癌的新兴治疗策略。
Expert Rev Anticancer Ther. 2023 Mar;23(3):243-256. doi: 10.1080/14737140.2023.2183844. Epub 2023 Mar 1.
6
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.NCCN 指南®洞察：胆道癌，第 2.2023 版。
J Natl Compr Canc Netw. 2023 Jul;21(7):694-704. doi: 10.6004/jnccn.2023.0035.
7
Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.肝胆肿瘤的生物标志物驱动和分子靶向治疗。
Semin Oncol. 2018 Jun;45(3):116-123. doi: 10.1053/j.seminoncol.2018.03.002. Epub 2018 Mar 16.
8
Top Hepatobiliary Articles from 2022 to Inform Your Cancer Practice.2022 年肝胆领域顶级文章，为您的癌症诊疗提供信息。
Ann Surg Oncol. 2024 Jan;31(1):75-80. doi: 10.1245/s10434-023-14420-4. Epub 2023 Oct 16.
9
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.新型靶向治疗策略在胆管癌和肝细胞癌中的应用。
Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20.
10
Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers.《外科肿瘤学年鉴实践指南系列：原发性肝脏和胆道癌的治疗》
Ann Surg Oncol. 2023 Dec;30(13):7935-7949. doi: 10.1245/s10434-023-14255-z. Epub 2023 Sep 11.
引用本文的文献
1
Simulating the tumor microenvironment-advances in building a vascularized model of hepatocellular carcinoma through 3D bioprinting.模拟肿瘤微环境——通过3D生物打印构建血管化肝细胞癌模型的进展
Hepatobiliary Surg Nutr. 2024 Oct 1;13(5):882-884. doi: 10.21037/hbsn-24-154. Epub 2024 Sep 26.
本文引用的文献
1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
2
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
3
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).肝细胞癌临床实践指南：日本肝脏学会2021版（第5版JSH-HCC指南）
Hepatol Res. 2023 May;53(5):383-390. doi: 10.1111/hepr.13892. Epub 2023 Mar 10.
4
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.联合检测 PIVKA-II 和 AFP 在亚太地区肝细胞癌监测和随访中的应用。
Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30.
5
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).手术与射频消融治疗小肝癌：一项随机对照试验（SURF试验）。
Liver Cancer. 2021 Dec 29;11(3):209-218. doi: 10.1159/000521665. eCollection 2022 Jun.
6
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study.基于日本全国性调查的扩大活体供肝肝移植标准用于肝细胞癌患者：5-5-500 规则-一项回顾性研究。
Transpl Int. 2019 Apr;32(4):356-368. doi: 10.1111/tri.13391. Epub 2019 Jan 18.
9
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
10
Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors.门静脉高压合并多发肿瘤患者的肝细胞癌肝切除术
Hepatol Res. 2018 May;48(6):433-441. doi: 10.1111/hepr.13047. Epub 2018 Jan 19.
Zotero 插件